Skip to content
Home/Companies/Biotech/Nitrase Therapeutics
Nitrase Therapeutics

Nitrase Therapeutics

Biotech·United States·Active·6yr hold
Entry
2020
Hold
6yr
Status
Active

Who owns Nitrase Therapeutics?

Nitrase Therapeutics is an American Biotech company, currently owned by Sofinnova Partners since 2020.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital IX · 2018 · Life Sciences VC

Key facts

HQUnited States
SectorBiotech
Websitenitrasetx.com

More from Sofinnova Capital IX

Other portfolio companies in the same fund.

Asceneuron
Active
BiotechSwitzerland· 2020
CorVent Medical
CorVent Medical
Active
MedTechUS· 2020
Genespire
Genespire
Active
BiotechItaly· 2020
Noema Pharma
Noema Pharma
Exited 2022
BiotechSwitzerland· 2020
to NOEMA PHARMA SA
Pi-Cardia
Pi-Cardia
Active
MedTechIsrael· 2020
Pyrowave
Pyrowave
Active
IndustrialsCanada· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Nitrase Therapeutics?

Nitrase Therapeutics is currently owned by Sofinnova Partners, through Sofinnova Capital IX, since 2020.

When did Sofinnova Partners acquire Nitrase Therapeutics?

Sofinnova Partners acquired Nitrase Therapeutics in 2020.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue